Certolizumab pegol (CZP) is a tumor necrosis factor-alpha (TNF- )-inhibitor recently registered for the treatment of moderate to severe plaque psoriasis in adults. The molecular structure of CZP differs from that of other TNF- -inhibitors because the Fc- fragment is missing, which, among other things is important for the transplacental transport of immunoglobulins (and the basis for these biologics). This quality makes CZP an important addition to the current treatment arsenal, especially for pregnant female patients (or a pregnancy wish) as it hardly passes through the placenta and will therefore not enter the fetal circulation.

, , ,
Nederlands Tijdschrift voor Dermatologie en Venereologie

Veldkamp, W.R. (W. R.), & van Doorn, M. (2019). Certolizumab pegol – Cimzia®. Nederlands Tijdschrift voor Dermatologie en Venereologie, 29(2), 30–33. Retrieved from http://hdl.handle.net/1765/122854